✦ LIBER ✦

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

✍ Scribed by L. Kappos; C.H. Polman; M.S. Freedman; G. Edan; H.P. Hartung; D.H. Miller; X. Montalban; F. Barkhof; L. Bauer; P. Jakobs; C. Pohl; R. Sandbrink

Book ID: 116201609
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 49 KB
Volume: 143
Category: Article
ISSN: 0002-9394
DOI: 10.1016/j.ajo.2006.11.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND15 COST-UTILITY OF INTERFERON BETA-1B

PND15 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS

✍ JP Caloyeras; C Wang; L Bauer; WC Lee; V Lanius; K Gondek 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

Good results for early treatment of clin

Good results for early treatment of clinically isolated syndrome prior to multiple sclerosis with interferon beta-1b and glatiramer group

✍ Doggrell, Sheila A 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 207 KB

PND26 COST-UTILITY OF INTERFERON BETA-1B

PND26 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS IN SPAIN

✍ T Arbizu; C Piñol; V Casado 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

The effect of interferon-beta1a on relap

The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis

✍ Mohammad Reza Motamed; Neda Najimi; Seyed-Mohammad Fereshtehnejad 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 210 KB

ND4 COST-UTILITY OF INTERFERON BETA-1B I

ND4 COST-UTILITY OF INTERFERON BETA-1B IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME SUGGESTIVE OF MULTIPLE SCLEROSIS: MODEL UTILIZING FIVE YEAR BENEFIT DATA

✍ JP Caloyeras; B Harrow; C Wang; K Beckmann; V Knappertz; C Pohl; JD Miller; MW R 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

A cost-effectiveness analysis of subcuta

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden

✍ Fredrikson, Sten; McLeod, Euan; Henry, Nathaniel; Pitcher, Ashley; Lowin, Julia; 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 759 KB